Skip to Content

Additional Content In This Section

SIRspheres

SIRspheres

Objective

Status

Enrollment complete

Condition
Colon Cancer and Rectal Cancer

Description

Randomized Comparative Study of FOLFOX6m plus SIR-SPHERES® MICROSPHERES versus FOLFOX6m alone as first line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma  

Purpose   

The study will evaluate the addition of Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres, to a standard systemic chemotherapy treatment regimen (FOLFOX6m) against the standard systemic chemotherapy treatment regimen alone (control arm) in patients with non-resectable liver metastases from primary colorectal carcinoma. Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, is permitted within this study at the discretion of the treating Investigator.

Phase
III

Key Inclusion Criteria

  • Unequivocal and measurable CT evidence of liver metastases which are not treatable by surgical resection or local ablation.
  • Limited extra-hepatic metastases in the lung and/or lymph nodes are permitted (Lung: 5 lesions total, < 1 cm, or 1 single lesion of up to 1.7 cm; Lymph nodules in one single anatomic area (pelvis, abdomen or chest): any number, < 2 cm).
  • Suitable for either treatment regimen.
  • Prior chemotherapy for metastatic colorectal cancer is not allowed.
  • WHO performance status 0-1.
  • Adequate hematological, renal and hepatic function.
  • Age 18 years or older.
  • Willing and able to provide written informed consent.
  • Life expectancy of at least 3 months without any active treatment.

Key Exclusion Criteria

  • Evidence of ascites, cirrhosis, portal hypertension, main portal or venous tumor involvement or thrombosis as determined by clinical or radiologic assessment.
  • Previous radiotherapy delivered to the upper abdomen.
  • Non-malignant disease that would render the patient unsuitable for treatment according to the protocol.
  • Peripheral neuropathy > grade 1 (NCI-CTC).
  • Dose limiting toxicity with previous adjuvant 5-FU or oxaliplatin chemotherapy.
  • Prior non-adjuvant chemotherapy for any malignancy. Adjuvant chemotherapy for colorectal cancer is not an exclusion criterion provided that it was completed more than 6 months before entry into the study.
  • Pregnant or breast-feeding.
  • Other active malignancy.

ClinicalTrials.gov Identifier

NCT00724503

IRB Protocol Number
STX0206
Principal Investigator(s)
Randall Smith, MD
Grant Seeger, MD

Clinical Trial Categories

  • Oncology
Sponsor(s)
Sirtex Technology
Contact
Renee Hendrickson, RN CCRC at 701-780-1694
or rhendrickson@altru.org